AAX Biotech appoints Patrik Strömberg to Board of Directors, enhancing leadership team
AAX Biotech is pleased to welcome Patrik Strömberg as new board member. Patrik Strömberg brings over two decades of extensive experience in the pharmaceutical industry, with a robust background in research and development, innovation management and business development.
AAX Biotech is a Swedish startup biotech company aiming to solve unmet needs in developing next-generation antibody therapeutics. The company’s two unique and patentable technologies, Seqitope™ and Opti-mAb™, improve the performance and developability of antibody-based therapeutics and offer a unique solution in a rapidly growing market.
Appointing Patrik Strömberg to the Board of Directors marks an important step in AAX Biotech’s strategic expansion as the company continues to build impactful collaborations with biotech and pharmaceutical partners. Patrik Strömberg’s substantial experience comes from key roles at pharmaceutical companies including AstraZeneca and Biovitrum/Sobi. Since 2021, Patrik Strömberg has served as the CEO of AnaCardio. He holds a PhD in Biochemistry from Karolinska Institutet and an MBA from Stockholm University.
“Patrik Strömberg’s comprehensive knowledge in both scientific and business aspects of the pharmaceutical industry makes him an invaluable addition to the board,” says Maria Lisa Knudsen, CEO of AAX Biotech. “His insights and leadership will be instrumental in accelerating our growth, enhancing our technological capabilities and solidifying our position in the global market.”
Patrik Strömberg comments: “I am excited to join the board of AAX Biotech and look forward to being a part of the journey ahead. With its innovative platforms and enabling technologies for biopharmaceutical drug development, AAX could provide the tools needed to discover transformational treatments across several therapeutic areas.”
This strategic expansion of the Board of Directors underscores AAX Biotech’s commitment to innovation and excellence in the biotechnology field.
For more information, please contact:
Maria Lisa Knudsen, CEO
+46 72 939 5018
maria.knudsen@aaxbiotech.com
About AAX Biotech AB
AAX Biotech AB is a biotech company specializing in next-generation antibody therapeutics. The company offers two unique and proprietary technologies, Seqitope™ and Opti-mAb™, that enable high-throughput and high-resolution epitope mapping as well as stabilization of single chain variable fragments (scFv) for applications such as bispecific antibodies and CAR-T cells. Both technologies aim to produce better and more effective antibody-based medicines. These innovations position AAX Biotech as a key player in the rapidly growing antibody therapeutics market. AAX Biotech is founded by experts from Karolinska Institutet in Stockholm, Sweden. Visit aaxbiotech.com to learn more and follow AAX on LinkedIn.
